Soligenix Inc. has completed a $7.5 million public offering that provides critical funding to advance the company's pipeline of rare disease treatments through 2026. The financing involved the sale of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with participation from existing and institutional healthcare investors. This capital infusion represents a strategic milestone for the late-stage biopharmaceutical company as it progresses multiple clinical programs targeting unmet medical needs.
The funding extends Soligenix's cash runway through the end of 2026, providing financial stability during a crucial period of clinical development and potential regulatory submissions. The company intends to allocate proceeds toward research and development, commercialization activities, working capital, and general corporate purposes. The offering also included amendments to prior warrants, adjusting their exercise price to $1.35 to align with current market conditions and investor expectations.
This financing supports Soligenix's Specialized BioTherapeutics business segment, which is advancing HyBryte™ (SGX301) toward potential commercialization for cutaneous T-cell lymphoma. The novel photodynamic therapy has completed its second Phase 3 study, positioning the company to seek regulatory approvals worldwide. Additional development programs include expanding synthetic hypericin into psoriasis treatment, developing dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and advancing SGX945 for Behçet's Disease.
The company's Public Health Solutions segment continues development of RiVax®, a ricin toxin vaccine candidate, along with vaccine programs targeting filoviruses such as Marburg and Ebola, and CiVax™ for COVID-19 prevention. These programs incorporate Soligenix's proprietary ThermoVax® heat stabilization platform technology and have received support through government grants and contracts from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. Additional information about the company's developments is available in their newsroom at https://ibn.fm/SNGX.
The successful financing demonstrates investor confidence in Soligenix's approach to addressing rare diseases and public health threats. For patients suffering from conditions with limited treatment options, such as cutaneous T-cell lymphoma and Behçet's Disease, this financial backing represents continued progress toward potentially life-changing therapies. The extended cash runway through 2026 provides the company with operational stability to navigate the complex regulatory pathway and advance multiple clinical programs simultaneously without immediate funding concerns.
